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Sir,
The letter from Kristen et al summarizes and confirms what we
wanted to communicate in this article. We are convinced that
sentinel node biopsy (SLNB) in experienced hands is a safe and
reliable method for axillary staging in a defined group of breast
cancer patients. But on the other hand, there are some aspects in
the SLNB technique that are not yet quite clear and well
understood. One of the questions is with regard to the pathological
assessment of SLNs. There are no standards on the number of
sections or the distance of sections of the SLN. We know that we
normally cannot miss a micrometastasis if we cut the SLN in serial
sections with distances less than 200mm. But what is the impact of
tumour cell emboli or single tumour cells in SLNs? What is the role
of immunohistochemistry or rPCR in the identification of tumour
cells? When is a negative SLN truly negative? We have no answers
for these questions and there are no accepted standards for the
pathological examination of SLNs. We have a lot of data for
identification rates of SLNs and a lot of data for false-negative
rates. We have less data for local or axillary recurrence-free
survival, and no data for disease-free survival and overall survival
of patients with SLNB alone in SLN-negative patients. There are
ongoing trials, which will answer these questions, and from the
scientific point of view, we should await the results of these trials
before we recommend the replacement of a standard treatment
procedure such as ALND by an innovative method such as SLNB.
Until we obtain these data, patients have to be informed about the
status of SLNB and patients should have the choice of deciding
between both treatment procedures. If we have evidence-based
data for the superiority of SLNB compared to ALND and if we have
standards for performing this fascinating technique, SLNB will be
appreciated as a standard procedure for axillary lymph node-
negative patients.
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